Chronic Lymphocytic Leukemia (CLL) is the most common type of leukemia in adults. The leukemia cells develop in the bone marrow but can go into the blood, from where it can spread to other parts of the body, like the lymph nodes, liver, and spleen. Often progressing slowly, awareness of CLL can lead to earlier diagnosis, which is crucial for managing the disease effectively. Join us in raising awareness during #BloodCancerAwarenessMonth. #ThisIsBloodCancer #CLL
About us
We are a biotechnology company with operations in Europe and the U.S. dedicated to developing transformational medicines for more years of life and quality of life. Focusing on high unmet medical needs, we synergize compelling science, technology, and collaborative approaches to create a deep pipeline of best-in-class small molecules, CAR-T therapies, and biologics in oncology and immunology. With capabilities from lab to patient, including a decentralized, point-of-care CAR-T manufacturing network, we are committed to challenging the status quo and delivering results for our patients, employees and shareholders.
- Website
-
http://www.glpg.com
External link for Galapagos
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Mechelen, Belgium
- Type
- Public Company
- Founded
- 1999
- Specialties
- biotech, R&D, Medicine discovery, Medicine development, Pharmaceuticals, and Drug Development
Locations
Employees at Galapagos
Updates
-
The most recent global data indicate there were an estimated 545,000 new cases of Non-Hodgkin Lymphoma (NHL) and 260,000 deaths in one year's time. 😔 NHL is a diverse group of blood cancers. It includes multiple subtypes that originate in the lymphatic system, which is part of the immune system. Join us in raising awareness during #BloodCancerAwarenessMonth. #ThisIsBloodCancer #NHL
-
Blood cancer is not just one disease. It’s a group of cancers that include #leukemia #lymphoma and #myeloma, each with their subtypes like Non-Hodgkin Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), and Multiple Myeloma (MM). These diseases can affect anyone, at any age, and at any time. Join us in raising awareness during #BloodCancerAwarenessMonth. #ThisIsBloodCancer
-
September marks Blood Cancer Awareness Month - a global initiative dedicated to raising awareness about one of the world’s most prevalent and dangerous cancers: blood cancer. Despite over a million people receiving a blood cancer diagnosis each year, awareness remains low. This month, we turn the spotlight on this complex group of diseases, which includes lymphoma, leukemia, and myeloma, to drive home the urgent need for more innovation, early diagnosis, and more awareness. Let’s unite to spread the word and make a difference for patients and their families. #BloodCancer #BloodCancerAwarenessMonth
-
Press release: https://lnkd.in/ez-Pc6jy | Galapagos announces FDA clearance of Investigational New Drug (IND) application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma #PioneeringForPatients
-
☎️ Ring ring! This is your call for purpose! Ready to contribute your expertise to interdisciplinary teams and fuel groundbreaking discoveries? Join us – an ambitious, international biotech company - on our quest for scientific breakthroughs. 🚀 Find your purpose today at www.workatgalapagos.com/ #IFoundMyPurpose #LivingInnovation #PioneeringForPatients
-
🚨 Calling all entrepreneurial spirits – this is your call for purpose! Be part of a biotech that shapes the future of healthcare. Join our team of passionate pioneers. It’s just a few clicks away… 🚀 Find your purpose today at www.workatgalapagos.com/ #IFoundMyPurpose #LivingInnovation #PioneeringForPatients
-
“A young, dynamic company with a biotech culture and a flat organization. Not your typical large pharma company, which I like.” We asked Marieke why she enjoys working at Galapagos. 🚀 For more stories from your future colleagues, visit https://lnkd.in/ejaN8dZb #IFoundMyPurpose #LivingInnovation #PioneeringForPatients
-
Investor or analyst? The replay of our H1 2024 Results webcast with our leadership is now available on https://lnkd.in/e9sSTZMM #PioneeringForPatients
-
Press release: https://lnkd.in/eKpTfHgY | Galapagos reports half-year 2024 financial results and provides second quarter business update. Join the webcast for investors and analysts on Friday 2 August, 14:00 CET / 08:00 ET. ℹ️Find the webcast details here: https://glpg.com/webcasts